The Predictive Value of Interim and Final [18F] Fluorodeoxyglucose Positron Emission Tomography after Rituximab-Chemotherapy in the Treatment of Non-Hodgkin's Lymphoma: A Meta-Analysis

<table>Forest plot of four included studies in DLBCL (F-PET, OS). Pooled effect (HR) and heterogeneity test of an F-PET-positive scan on OS in a majority of DLBCL patients (PET: positron emission tomography; OS: overall survival; HR: hazard ratio; DLBCL: diffuse large B-cell lymphoma).</table>

BioMed Research International

fig5

Figure 5

Figure 5: The Predictive Value of Interim and Final [18F] Fluorodeoxyglucose Positron Emission Tomography after Rituximab-Chemotherapy in the Treatment of Non-Hodgkin's Lymphoma: A Meta-Analysis 

Figure 5 | The Predictive Value of Interim and Final [18F] Fluorodeoxyglucose Positron Emission Tomography after Rituximab-Chemotherapy in the Treatment of Non-Hodgkin's Lymphoma: A Meta-Analysis 